ASH Marvin Moser Clinical Hypertension Award
ASH announced a new award in 2009, the Marvin Moser Clinical Hypertension Award. The Society will recognize a qualified Hypedrtension Clinician for his or her dedication to the treatment and care of hypertensive patients. The award will be given at the ASH Annual Scientific Meeting. The award recipient will receive a $5,000 honorarium, given by the Hypertension Education Foundation, as well as complimentary registration to the ASH Annual Scientific Meeting and reimbursement for travel expenses and hotel accommodations for two nights to attend the Annual Meeting. In addition, the award recipient will be recognized at the ASH Annual Scientific Meeting during the Awards Plenary Session.
Qualifications
Candidate:
 |
Must have been involved in treating hypertensive patients as a major component of his or her practice experience |
|
Must be currently active in teaching |
|
May have had an active role in developing guidelines and in clinical trials that focus on improving blood pressure control |
|
May be involved in community programs |
Application Requirements
|
Only ASH Members can nominate candidates |
|
Sponsor submission of complete name, address, phone/fax numbers, and e-mail address of nominee |
|
Signed letter of nomination articulating major contributions of nominee to the treatment and care of hypertensive patients |
|
At least one additional supporting letter |
|
Complete curriculum vitae |
Please send all nomination materials to:
Ashley Buron
Program Coordinator
American Society of Hypertension, Inc.
148 Madison Ave. , 5th Floor
New York , NY 10016
awards@ash-us.org
212-696-9099
The American Society of Hypertension is pleased to announce the recipient of the ASH Marvin Moser Clinical Hypertension Award. This award recognizes a qualified Hypertension Clinician for his or her dedication to the treatment and care of hypertensive patients.
The 2011 Award was presented during the ASH Twenty-Sixth Annual Scientific Meeting during the Awards Plenary Session on Monday, May 23rd, 2011.
2011 Award Recipient
Murray Epstein, MD, FASH
Professor of Medicine, University of Miami, School of Medicine
Murray Epstein, MD, FASH is Professor of Medicine at the University of Miami, School of Medicine. He was a recipient of the 1990 Distinguished Scientist Award of the National Kidney Foundation. He served as a member of the National High Blood Pressure Education Program Coordinating Committee and is a contributor to the 6th Report of the Joint National Committee. Dr. Epstein is listed in Who's Who in America (59th, 60th and 61st edition) and Who's Who in Medicine.
Dr. Epstein has authored over 400 journal articles and book chapters. Many of these have related to 1) the pathogenesis and management of hypertension, 2) renal function in diseases characterized by abnormal volume regulation, and 3) the role of the renin‑angiotensin‑aldosterone system. He has also written extensively on head‑out water immersion, a unique clinical investigational model that he has defined and applied to the study of a wide range of disease states. The unique attributes of this clinical investigative model include a prompt redistribution of circulating blood volume with a consequent relative central hypervolemia, in the absence of concomitant changes in plasma composition. Dr. Epstein has successfully applied the immersion model as a clinical investigative tool to characterize the determinants of deranged volume homeostasis and renin-aldosterone, eicosanoid, kallikrein, vasopressin and ANF responsiveness in diverse edematous disorders including advanced liver diseases, chronic renal failure and hypertension. He has also utilized the immersion model to define the relative roles of volume and the renin-angiotensin axis as determinants of aldosterone responsiveness in anephric humans.
Dr. Epstein has also defined the effects of calcium antagonists on renal hemodynamics and renal function At the preclinical level Dr. Epstein, in collaboration with his co-investigator Dr. Rodger Loutzenhiser, developed and used the isolated perfused hydronephrotic kidney model to visualize the renal microvasculature and define the effect of interventions with calcium antagonists and a wide array of vasoconstrictors including angiotensin II and endothelin on the afferent and efferent arterioles. He extended these studies to the clinical arena in order to define the effect of calcium antagonists on renal hemodynamics and as prophylactic agents to obviate acute renal failure in diverse clinical settings. Most recently Dr. Epstein has focused his clinical and investigative attention on the role of aldosterone as a pivotal determinant of cardiovascular and renal injury, and the use of aldosterone blockade to reverse these adverse effects. Currently his major investigative focus is on mineralocorticoid receptor blockade as an intervention to abrogate progressive kidney disease, and as an intervention to confer cardiovascular and renal benefits in patients with chronic kidney disease, and in ESRD patients who are being treated by hemodialysis.
A member of several editorial boards, Dr. Epstein also serves as a reviewer for numerous prominent journals and for study sections for granting agencies.